Journal List > Korean J Clin Microbiol > v.13(3) > 1038189

Korean J Clin Microbiol. 2010 Sep;13(3):114-120. Korean.
Published online September 30, 2010.
Copyright © 2010 The Korean Society of Clinical Microbiology
Comparison of ATB FUNGUS 2 and VITEK-2 Antifungal Susceptibility (AST-YS01) Tests for Candida Species Isolated from Blood Culture
Soon Deok Park,1 Young Uh,1 In Ho Jang,1 Kap Jun Yoon,1 and Jong Hee Shin2
1Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
2Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea.

Correspondence: Young Uh, Department of Laboratory Medicine, Wonju Christian Hospital, 162 Ilsan-dong, Wonju 220-701, Korea. (Tel) 82-33-741-1592, (Fax) 82-33-731-0506, Email:
Received January 22, 2010; Revised April 30, 2010; Accepted June 18, 2010.



The VITEK-2 yeast susceptibility test (AST-YS01; bioMérieux, Hazelwood, MO, USA) has recently been introduced as a fully automated, commercial antifungal susceptibility test system that determines MIC endpoints spectrophotometrically, thereby eliminating subjective errors. We compared the ATB FUNGUS 2 (bioMérieux) and VITEK-2 (AST-YS01) systems to the CLSI M27 method for susceptibility testing of Candida isolates.


We tested 59 Candida species that were isolated from blood cultures at Wonju Christian Hospital between September 2008 and August 2009. We compared MIC results for amphotericin B, flucytosine, fluconazole and voriconazole using the ATB FUNGUS 2 and VITEK-2 (AST-YS01) tests to those obtained by the CLSI M27 broth microdilution method.


Within two-fold dilutions of MICs, the agreement of the ATB FUNGUS 2 and VITEK-2 (AST-YS01) tests with the CLSI method according to antifungal agents were: amphotericin B, 100% vs. 100% flucytosine, 100% vs. 100% fluconazole, 83.6% vs. 98.3% and voriconazole, 83.6% vs. 96.7%, respectively. The categorical discrepancies for fluconazole and voriconazole were 20.4% and 18.6% for ATB FUNGUS 2, and 6.8% and 0% for VITEK-2 (ASTYS01). There were no major errors for fluconazole and voriconazole in either ATB FUNGUS 2 or VITEK-2 (AST-YS01) tests.


The VITEK-2 system (AST-YS01) appears to be rapid and highly correlative with the CLSI method, suggesting that it is effective for antifungal susceptibility testing for Candida species in clinical settings.

Keywords: Antifungal susceptibility; Blood culture; Candida species; VITEK-2; ATB FUNGUS 2; CLSI


Table 1
In vitro susceptibilities of 59 isolates of Candida spp. to amphotericin B, flucytosine, fluconazole and voriconazole as determined with the ATB FUNGUS 2 and VITEK-2 (AST-YS01) system, and by CLSI M27 BMD methods
Click for larger image

Table 2
Categorical agreement of flucytosine, fluconazole and voriconazole MICs determined by two commercial antifungal tests and CLSI M27 BMD method for 59 isolates of Candida spp.
Click for larger image

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317.
2. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001;14:643–658.
3. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. Third ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. M27-A3.
4. Kim DW, Shin JH, Kee SJ, Kim SH, Shin MG, Suh SP, et al. Evaluation of VITEK-2 antifungal susceptibility test (AST-YS01) for Candida species isolates in Korea. Korean J Clin Microbiol 2009;12:122–128.
5. Uh Y, Kim HY, Yoon KJ. In: Antimicrobial agents and antimicrobial susceptibility test. 1st ed. Paju: KIS; 2007. pp. 596-611.
6. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007;48:779–786.
7. Quindós G, Salesa R, Carrillo-Muñoz AJ, Lipperheide V, Jáudenes L, San Millán R, et al. Multicenter evaluation of ATB fungus: a standardized micromethod for yeast susceptibility testing. Chemotherapy 1994;40:245–251.
8. Philpot CM, Charles D. Determination of sensitivity to antifungal drugs: evaluation of an API kit. Br J Biomed Sci 1993;50:27–30.
9. Shin JH, Lim WH, Shin DH, Suh SP, Ryang DW. Antifungal susceptibilities to fulconazole and itraconazole for Candida species recovered from blood cultures over a 5-year period. Korean J Infect Dis 2000;32:179–185.
10. Chae JD, Kang JO, Eom JI, Park IK, Choi TY. Amphotericin B and fluconazole susceptibility test of Candida species: comparison of broth microdilution method and agar dilution method. Korean J Clin Pathol 2000;20:392–399.
11. Kim YS, Lee HJ, Lee JR, Kang BK, Lee WI, Kil YC, et al. Comparative evaluation of fluconazole susceptibility methods for Candida species: broth microdilution test, E test and disk diffusion test. Korean J Clin Pathol 2000;20:36–40.
12. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007;45:796–802.
13. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007;45:3522–3528.
14. Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. Rockville, MD: Food and Drug Administration; 2007.